NCT06280755 Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
| NCT ID | NCT06280755 |
| Status | Recruiting |
| Phase | — |
| Sponsor | icometrix |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,000 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,000 participants in total. It began in 2024-03-01 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.
Eligibility Criteria
Inclusion criteria: * Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS or RIS. * Patient (or patient's legal representative) has previously signed and dated an informed consent form (ICF) for the secondary use of their data, or assent form. Alternatively, the secondary use of the patient's data is allowed following Institutional Review Board (IRB)/Ethical Committee (EC) approval in accordance with national and local subject privacy regulations. Exclusion criteria: * Patients under 18 years of age will be excluded. * Other unspecified reasons that, in the opinion of the Investigator or Joint Steering Committee, make the patient unsuitable for participation in the study.
Contact & Investigator
Friedemann Paul, PhD, MD
PRINCIPAL INVESTIGATOR
Max Delbrück Center - Charite University, Berlin, Germany
Frequently Asked Questions
Who can join the NCT06280755 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06280755 currently recruiting?
Yes, NCT06280755 is actively recruiting participants. Contact the research team at diana.sima@icometrix.com for enrollment information.
Where is the NCT06280755 trial being conducted?
This trial is being conducted at Prague, Czechia, Bochum, Germany, Berlin, Germany.
Who is sponsoring the NCT06280755 clinical trial?
NCT06280755 is sponsored by icometrix. The principal investigator is Friedemann Paul, PhD, MD at Max Delbrück Center - Charite University, Berlin, Germany. The trial plans to enroll 7,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.